Alpha Tau Is Building the Local Answer to Pancreatic Cancer’s Systemic Breakthrough
After encouraging early pancreatic data, demand for Alpha DaRT helped quadruple its IMPACT study from 12 patients to 48 as the company moves toward a pivotal trial.
Section
Wall Street Wire
Paid Wall Street Wire reports.